DK1328271T3 - Behandling af neurologiske og neurofysiologiske sygdomme - Google Patents

Behandling af neurologiske og neurofysiologiske sygdomme

Info

Publication number: DK1328271T3
Authority: DK; Denmark
Prior art keywords: npy; activity; treatment; reduction; functionally active
Prior art date: 2000-10-27

Application number

DK01988583T

Other languages

Danish (da)

English (en)

Inventor

Horsten Stephan Von

Hans-Ulrich Demuth

Matthias Hoffmann

Susanne Kruber

Huu Phuc Nguyen

Ants Kask

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-27

Filing date

2001-10-29

Publication date

2008-10-13

2001-10-29 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2008-10-13 Application granted granted Critical

2008-10-13 Publication of DK1328271T3 publication Critical patent/DK1328271T3/da

Links

201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000001537 neural effect Effects 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title abstract 2
101710151321 Melanostatin Proteins 0.000 abstract 3
102400000064 Neuropeptide Y Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 3
208000019901 Anxiety disease Diseases 0.000 abstract 1
102100027936 Attractin Human genes 0.000 abstract 1
101710134735 Attractin Proteins 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
102000001708 Protein Isoforms Human genes 0.000 abstract 1
108010029485 Protein Isoforms Proteins 0.000 abstract 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
230000001364 causal effect Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
230000003001 depressive effect Effects 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
206010022437 insomnia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 abstract 1
BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Thiazole And Isothizaole Compounds (AREA)

DK01988583T 2000-10-27 2001-10-29 Behandling af neurologiske og neurofysiologiske sygdomme DK1328271T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24403600P	2000-10-27	2000-10-27
PCT/EP2001/012479 WO2002034243A2 (fr)	2000-10-27	2001-10-29	Procede pour le traitement de troubles neurologiques et neuropsychologiques

Publications (1)

Publication Number	Publication Date
DK1328271T3 true DK1328271T3 (da)	2008-10-13

Family

ID=22921137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01988583T DK1328271T3 (da)	2000-10-27	2001-10-29	Behandling af neurologiske og neurofysiologiske sygdomme

Country Status (19)

Country	Link
US (1)	US20040043919A1 (fr)
EP (2)	EP1328271B1 (fr)
JP (2)	JP2004512299A (fr)
KR (2)	KR20040025875A (fr)
CN (3)	CN1471392A (fr)
AT (1)	ATE399008T1 (fr)
AU (3)	AU2177302A (fr)
BR (2)	BR0114921A (fr)
CA (3)	CA2422889C (fr)
CY (1)	CY1108336T1 (fr)
DE (1)	DE60134563D1 (fr)
DK (1)	DK1328271T3 (fr)
ES (1)	ES2309108T3 (fr)
IL (4)	IL155157A0 (fr)
NO (2)	NO20031849L (fr)
PT (1)	PT1328271E (fr)
RU (3)	RU2286149C2 (fr)
WO (2)	WO2002034242A2 (fr)
ZA (2)	ZA200302394B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2285785T3 (es) *	1997-09-29	2007-11-16	Point Therapeutics, Inc.	Estimulacion de celulas hematopoyeticas in vitro.
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
JP2004512299A (ja) *	2000-10-27	2004-04-22	プロバイオドラッグ　アーゲー	神経学的および神経心理学的疾患の治療方法
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
IL158923A0 (en)	2001-06-27	2004-05-12	Smithkline Beecham Corp	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
CA2481995A1 (fr)	2002-04-08	2003-10-16	Torrent Pharmaceuticals Ltd.	Thiazolidine-4-carbonitriles et analogues et leur utilisation comme inhibiteurs de dipeptidyl-peptidas
US20050084490A1 (en) *	2002-07-09	2005-04-21	Point Therapeutics, Inc.	Boroproline compound combination therapy
WO2004087053A2 (fr)	2003-03-25	2004-10-14	Syrrx, Inc.	Inhibiteurs de dipeptidyle peptidase
KR20100038477A (ko)	2003-05-05	2010-04-14	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
ATE464889T1 (de)	2003-05-05	2010-05-15	Probiodrug Ag	Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005016911A1 (fr)	2003-08-13	2005-02-24	Takeda Pharmaceutical Company Limited	Derives de 4-pyrimidone et leur utilisation en tant qu'inhibiteurs de la peptidyle peptidase
WO2005026148A1 (fr)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Inhibiteurs de la dipeptidylpeptidase
NZ546322A (en)	2003-10-15	2008-11-28	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
NZ549716A (en)	2004-03-15	2010-04-30	Takeda Pharmaceutical	Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (fr)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Inhibiteurs de la dipeptidyl peptidase
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
WO2006068978A2 (fr)	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Inhibiteurs de dipeptidyle peptidase
ES2376351T5 (es)	2005-09-14	2014-07-15	Takeda Pharmaceutical Company Limited	Inhibidores de la dipeptidil-peptidasa para el tratamiento de la diabetes
CN102675221A (zh)	2005-09-16	2012-09-19	武田药品工业株式会社	用于制备嘧啶二酮衍生物的方法中的中间体
WO2007112347A1 (fr)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Inhibiteurs de la dipeptidyl peptidase
BRPI0709984A2 (pt)	2006-04-12	2011-08-02	Probiodrug Ag	inibidores de enzima
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
RU2350331C1 (ru) *	2007-07-10	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения невроза навязчивых состояний
RU2350330C1 (ru) *	2007-11-13	2009-03-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения истерического невроза
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
CA2771352A1 (fr)	2009-09-02	2011-03-10	Merck Sharp & Dohme Corp.	Aminotetrahydropanes utilises comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prevenir le diabete
CN102791701B (zh)	2009-12-30	2014-02-12	深圳信立泰药业股份有限公司	作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
EP2538783B1 (fr)	2010-02-22	2016-06-01	Merck Sharp & Dohme Corp.	Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
EP2571876B1 (fr)	2010-05-21	2016-09-07	Merck Sharp & Dohme Corp.	Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
US9073930B2 (en)	2012-02-17	2015-07-07	Merck Sharp & Dohme	Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9668969B1 (en)	2012-02-22	2017-06-06	Arturo Solis Herrera	Methods of using QIAPINE
WO2014018350A1 (fr)	2012-07-23	2014-01-30	Merck Sharp & Dohme Corp.	Traitement du diabète par administration d'inhibiteurs de dipeptidyl peptidase-iv
CN107213465A (zh) *	2017-06-23	2017-09-29	武汉大学	二肽基肽酶iv抑制剂在制备防治癫痫的药物中的应用
CN119380997B (zh) *	2024-12-27	2025-03-21	内蒙古医科大学附属医院(内蒙古自治区心血管研究所)	一种神经内科康复程度评价方法及系统

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US25023A (en) *		1859-08-09		Improved device for making electro-magnetic currents, constant or intermittent
US2961377A (en) *	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en) *	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (fr) *	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en) *	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en) *	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
DE4039415A1 (de) *	1990-02-03	1991-08-08	Boehringer Mannheim Gmbh	Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
IL106998A0 (en) *	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en) *	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) *	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE19616486C5 (de) *	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP2002501889A (ja) *	1998-02-02	2002-01-22	トラスティーズオブタフツカレッジ	グルコース代謝を調節する方法、およびそれに関連する試薬
JP2002506075A (ja) *	1998-03-09	2002-02-26	フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ	セリンペプチダーゼ調節剤
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000053171A1 (fr) *	1999-03-05	2000-09-14	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Utilisation de metformine dans la preparation de compositions pharmaceutiques pouvant inhiber l'enzyme dipeptidyl peptidase iv
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
HU229042B1 (en) *	2000-03-31	2013-07-29	Prosidion Ltd	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
JP2004512299A (ja) *	2000-10-27	2004-04-22	プロバイオドラッグ　アーゲー	神経学的および神経心理学的疾患の治療方法

2001
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/ja not_active Withdrawn
- 2001-10-29 DK DK01988583T patent/DK1328271T3/da active
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/fr not_active Ceased
- 2001-10-29 CA CA2422889A patent/CA2422889C/fr not_active Expired - Fee Related
- 2001-10-29 PT PT01988583T patent/PT1328271E/pt unknown
- 2001-10-29 CA CA002689012A patent/CA2689012A1/fr not_active Abandoned
- 2001-10-29 IL IL15515701A patent/IL155157A0/xx unknown
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/ru not_active IP Right Cessation
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/ja active Pending
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/ko not_active Withdrawn
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/pt not_active Application Discontinuation
- 2001-10-29 AU AU2177302A patent/AU2177302A/xx active Pending
- 2001-10-29 ES ES01988583T patent/ES2309108T3/es not_active Expired - Lifetime
- 2001-10-29 IL IL15511601A patent/IL155116A0/xx unknown
- 2001-10-29 CA CA002424475A patent/CA2424475A1/fr not_active Abandoned
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/fr not_active Ceased
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 DE DE60134563T patent/DE60134563D1/de not_active Expired - Lifetime
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/ko not_active Ceased
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/zh active Pending
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/pt not_active IP Right Cessation
- 2001-10-29 EP EP01988583A patent/EP1328271B1/fr not_active Expired - Lifetime
- 2001-10-29 CN CNB018180671A patent/CN1278683C/zh not_active Expired - Fee Related
- 2001-10-29 EP EP01988582A patent/EP1328270A2/fr not_active Withdrawn
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/ru not_active Application Discontinuation
- 2001-10-29 AT AT01988583T patent/ATE399008T1/de active
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/zh active Pending
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/no unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/no not_active Application Discontinuation
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/ru not_active IP Right Cessation
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/el unknown
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown

Also Published As

Publication number	Publication date
DE60134563D1 (de)	2008-08-07
BR0114924A (pt)	2003-12-23
AU2002227898A1 (en)	2002-05-06
JP2004512300A (ja)	2004-04-22
BR0114921A (pt)	2003-12-23
HK1062643A1 (en)	2004-11-19
CN1471392A (zh)	2004-01-28
AU2002221773B2 (en)	2005-12-22
WO2002034243A3 (fr)	2003-01-30
KR20040025875A (ko)	2004-03-26
JP2004512299A (ja)	2004-04-22
RU2003115614A (ru)	2004-10-27
EP1328271B1 (fr)	2008-06-25
PT1328271E (pt)	2008-08-26
NO20031849L (no)	2003-06-23
ZA200302590B (en)	2004-04-02
IL155157A0 (en)	2003-10-31
RU2286149C2 (ru)	2006-10-27
CA2422889A1 (fr)	2002-05-02
IL196994A0 (en)	2011-07-31
NO20031849D0 (no)	2003-04-24
ES2309108T3 (es)	2008-12-16
ATE399008T1 (de)	2008-07-15
ZA200302394B (en)	2004-03-29
US20040043919A1 (en)	2004-03-04
EP1328270A2 (fr)	2003-07-23
IL155116A0 (en)	2003-10-31
CN1471393A (zh)	2004-01-28
IL155116A (en)	2009-09-01
CY1108336T1 (el)	2014-02-12
RU2416406C2 (ru)	2011-04-20
CN1278683C (zh)	2006-10-11
RU2006122179A (ru)	2007-12-27
CA2422889C (fr)	2010-01-26
WO2002034242A2 (fr)	2002-05-02
EP1328271A2 (fr)	2003-07-23
NO20031867D0 (no)	2003-04-25
CA2689012A1 (fr)	2002-05-02
WO2002034242A3 (fr)	2003-01-30
AU2177302A (en)	2002-05-06
CA2424475A1 (fr)	2002-05-02
WO2002034243A2 (fr)	2002-05-02
CN101143217A (zh)	2008-03-19
NO20031867L (no)	2003-06-19
KR20030096227A (ko)	2003-12-24

Publication	Publication Date	Title
DK1328271T3 (da)	2008-10-13	Behandling af neurologiske og neurofysiologiske sygdomme
DE60027431D1 (de)	2006-05-24	Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE298566T1 (de)	2005-07-15	Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DK0971713T3 (da)	2003-09-22	Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE60324449D1 (de)	2008-12-11	Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
AR019011A1 (es)	2001-12-26	Inhibidores de las caspasas, composiciones farmaceuticas que comprenden estos inhibidores, metodos para inhibir la actividad de caspasa, disminuir laproduccion de 161f, disminuir la produccion de ifn-gama y para tratar interleukina 1, enfermedades mediadas por apoptosis e interferon-gama usando dich
DE69616375D1 (de)	2001-11-29	Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
NO20044470L (no)	2004-11-04	Terapeutisk anvendelse av selektive PDE 10 inhibitorer
ATE356804T1 (de)	2007-04-15	Inhibitoren von mitotischem kinesin
ATE372341T1 (de)	2007-09-15	Inhibitoren von mitotischem kinesin
ATE443758T1 (de)	2009-10-15	Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
MXPA05006359A (es)	2006-02-08	Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
DE60228278D1 (de)	2008-09-25	Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
DK1478380T3 (da)	2006-11-27	Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
ATE356634T1 (de)	2007-04-15	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE60008753D1 (de)	2004-04-08	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
MA58653B1 (fr)	2024-02-29	Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6
EP1372648A4 (fr)	2004-09-01	Inhibiteurs de recepteur kinase tie2 pour le traitement des maladies angiogeniques
HUP0401154A2 (hu)	2004-10-28	NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására
ATE311901T1 (de)	2005-12-15	Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten